At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 250 enrolled
Drug / intervention
GSK189075 +1 moredrug
Likely dose
GSK189075 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
In Brief
A Phase 2 clinical trial evaluating GSK189075 and Placebo for Diabetes Mellitus, Type 2. Completed, enrolled 250 participants across 157 sites in 16 countries.
Detailed Summary
This is a dose-ranging study to evaluate the efficacy, safety and tolerability of a range of doses of GSK189075 (an SGLT2 inhibitor) compared to placebo, administered over 12 weeks in treatment-naive subjects with type 2 diabetes mellitus
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesCanada, Czechia, Estonia, Germany, Greece, India, Lithuania, Mexico, New Zealand, Poland, Puerto Rico, Romania, Russia, South Africa, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2007
Enrollment StartAug 2007
Primary CompletionJun 2008
TodayJul 2026
First PostedJul 3, 2007
Enrollment StartAug 17, 2007
Primary CompletionJun 5, 2008
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 19.0 years ago
Interventions
GSK189075drug
GSK189075 is available as a white, capsule-shaped tablet dosage form containing 50mg, 125mg, 250mg or 500mg of GSK189075 per tablet
Placebodrug
Available as Placebo matching tablet to GSK189075